{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neck+Neoplasms&page=54",
    "query": {
      "condition": "Neck Neoplasms",
      "page": 54
    },
    "page_size": 10
  },
  "pagination": {
    "page": 54,
    "page_size": 10,
    "total_count": 4129,
    "total_pages": 413,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neck+Neoplasms&page=55&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neck+Neoplasms&page=53&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T18:31:26.697Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01770353",
      "title": "MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors",
        "ER/PR Positive Breast Cancer",
        "Triple Negative Breast Cancer",
        "Metastatic Breast Cancer With Active Brain Metastasis"
      ],
      "interventions": [
        {
          "name": "Ferumoxytol",
          "type": "DRUG"
        },
        {
          "name": "MM-398",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ipsen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2012-11",
      "completion_date": "2018-10-02",
      "has_results": true,
      "last_update_posted_date": "2019-11-27",
      "last_synced_at": "2026-11-15T18:31:26.697Z",
      "location_count": 7,
      "location_summary": "Scottsdale, Arizona • San Francisco, California • Tampa, Florida + 3 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01770353"
    },
    {
      "nct_id": "NCT05077709",
      "title": "IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer Non Small Cell",
        "Head and Neck Squamous Cell Carcinoma",
        "Urothelial Carcinoma Bladder"
      ],
      "interventions": [
        {
          "name": "IO102-IO103 in combination with pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "IO Biotech",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2022-04-11",
      "completion_date": "2026-02-08",
      "has_results": true,
      "last_update_posted_date": "2026-04-08",
      "last_synced_at": "2026-11-15T18:31:26.697Z",
      "location_count": 9,
      "location_summary": "Duarte, California • Sacramento, California • San Diego, California + 6 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Orange City",
          "state": "Florida"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05077709"
    },
    {
      "nct_id": "NCT00139243",
      "title": "Study of Taxotere, Cisplatin, 5-Fluorouracil, and Leucovorin for Squamous Cell Carcinoma of the Head and Neck",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Squamous Cell Carcinoma",
        "Carcinoma of Head and/or Neck"
      ],
      "interventions": [
        {
          "name": "Taxotere",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "5-Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "1997-10",
      "completion_date": "2006-01",
      "has_results": false,
      "last_update_posted_date": "2008-06-04",
      "last_synced_at": "2026-11-15T18:31:26.697Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00139243"
    },
    {
      "nct_id": "NCT05975593",
      "title": "MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Locally Advanced Cervical Carcinoma",
        "Locally Advanced Cervical Cancer",
        "Locally Advanced Pancreas Cancer",
        "Locally Advanced Pancreatic Carcinoma",
        "Locally Advanced Pancreatic Cancer",
        "Cervical Cancer",
        "Pancreas Cancer",
        "Pancreatic Cancer",
        "Cancer of the Cervix",
        "Cancer of the Pancreas"
      ],
      "interventions": [
        {
          "name": "Tumor collection via biopsy",
          "type": "OTHER"
        },
        {
          "name": "Blood collection",
          "type": "OTHER"
        },
        {
          "name": "Diffusion basis spectrum imaging (DBSI) magnetic resonance imaging (MRI)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DEVICE"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2024-01-11",
      "completion_date": "2032-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-17",
      "last_synced_at": "2026-11-15T18:31:26.697Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05975593"
    },
    {
      "nct_id": "NCT03613493",
      "title": "Acceptability of Human Papillomavirus (HPV) Self-sampling Tools for Cervical Cancer Prevention",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cervical Cancer"
      ],
      "interventions": [
        {
          "name": "HPV self-sampling kit",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Culturally-targeted Fear Appeal Message",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Fear Appeal Message",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Interview",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST",
        "BEHAVIORAL"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "30 Years to 65 Years · Female only"
      },
      "enrollment_count": 175,
      "start_date": "2018-07-10",
      "completion_date": "2018-10-01",
      "has_results": true,
      "last_update_posted_date": "2019-08-02",
      "last_synced_at": "2026-11-15T18:31:26.697Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03613493"
    },
    {
      "nct_id": "NCT04430738",
      "title": "Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Carcinoma",
        "Gastric Adenocarcinoma",
        "GEJ Adenocarcinoma",
        "Esophageal Adenocarcinoma",
        "Cholangiocarcinoma",
        "Gallbladder Carcinoma"
      ],
      "interventions": [
        {
          "name": "tucatinib",
          "type": "DRUG"
        },
        {
          "name": "trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "leucovorin",
          "type": "DRUG"
        },
        {
          "name": "fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "capecitabine",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen, a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2020-09-15",
      "completion_date": "2026-12-31",
      "has_results": true,
      "last_update_posted_date": "2026-02-24",
      "last_synced_at": "2026-11-15T18:31:26.697Z",
      "location_count": 21,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Aurora, Colorado + 10 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04430738"
    },
    {
      "nct_id": "NCT06357858",
      "title": "ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Squamous Cell Carcinoma of the Head and Neck",
        "Metastatic Squamous Cell Carcinoma",
        "Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "INQOVI (decitabine and cedazuridine)",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2024-06-01",
      "completion_date": "2026-02-28",
      "has_results": false,
      "last_update_posted_date": "2024-07-03",
      "last_synced_at": "2026-11-15T18:31:26.697Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06357858"
    },
    {
      "nct_id": "NCT04681248",
      "title": "Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Esophageal Neoplasm",
        "Adenocarcinoma of the Gastroesophageal Junction",
        "GastroEsophageal Cancer",
        "Squamous Cell Carcinoma",
        "Gastric Adenocarcinoma",
        "Endometrial Cancer",
        "Uterine Cancer",
        "Ovarian Cancer",
        "Carcinosarcoma",
        "Gastric Cancer"
      ],
      "interventions": [
        {
          "name": "DKN-01",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Leap Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2025-08-03",
      "last_synced_at": "2026-11-15T18:31:26.697Z",
      "location_count": 5,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 2 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04681248"
    },
    {
      "nct_id": "NCT03515538",
      "title": "Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Oral Mucositis"
      ],
      "interventions": [
        {
          "name": "RRx-001",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin for injection",
          "type": "DRUG"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "EpicentRx, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 53,
      "start_date": "2018-07-12",
      "completion_date": "2020-10-08",
      "has_results": true,
      "last_update_posted_date": "2024-11-04",
      "last_synced_at": "2026-11-15T18:31:26.697Z",
      "location_count": 12,
      "location_summary": "Santa Monica, California • Denver, Colorado • Washington D.C., District of Columbia + 9 more",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03515538"
    },
    {
      "nct_id": "NCT02408887",
      "title": "Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in People With Low-risk Papillary Thyroid Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Low-risk Papillary Thyroid Cancer",
        "Endocrine Malignancy",
        "Thyroid Cancer"
      ],
      "interventions": [
        {
          "name": "Total Thyroidectomy (TT)",
          "type": "PROCEDURE"
        },
        {
          "name": "Prophylactic central neck lymph node dissection (pCND)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2015-04-15",
      "completion_date": "2019-05-07",
      "has_results": true,
      "last_update_posted_date": "2022-09-27",
      "last_synced_at": "2026-11-15T18:31:26.697Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02408887"
    }
  ]
}